• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Hamilton General Hospital,Hamilton Health Sciences

    EST. 1848
    490论文总数
    5.9万引用总数

    The Hamilton General Hospital (HGH) is a major teaching hospital in Downtown Hamilton, Ontario, Canada, located at the intersection of Barton Street East and Victoria Avenue North. It is operated by Hamilton Health Sciences and is formally affiliated with the Michael G. DeGroote School of Medicine at McMaster University.HGH has a high acute and emergency care burden, as 53.7% of patients are admitted through the emergency department (2020-2021). In 2020-2021, the average length of stay was 7.6 days and number of acute admissions was 45,165. HGH is one of the largest cardiac surgical centres in Canada, performing over 1,600 open heart surgeries annually. The hospital generated C$182,000,000 of research income in 2013, second to the University Health Network amongst research hospitals in Canada, and representing 14.8% of its income.HGH is also one of the largest trauma, neurosurgery, and stroke centres in Canada. They perform over 1000 neurosurgical procedures annually. It is an accredited centre of Distinction in Stroke Services for demonstrating clinical excellence in Acute Stroke Services and Inpatient Stroke Rehabilitation Services.

    论文量&引用量时间轴

    机构学者

    论文(490)

    年份
    起
    –
    止
    排序
    1Bleeding Risk with Apixaban Vs. Rivaroxaban in Acute Venous Thromboembolism.
    Lana A Castellucci,Vivien M Chen, Michael J Kovacs,Alejandro Lazo-Langner, Peter Greenstreet,Susan Kahn, Benoit Côté,Sam Schulman,Kerstin de Wit, James Douketis,Deepa Suryanarayan,Tony Wan,

    BACKGROUND:Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications. METHODS:In an international trial with a prospective, randomized, open-label, blinded end-point design, we assigned, in a 1:1 ratio, eligible patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis to receive apixaban or rivaroxaban for 3 months. Apixaban was given at a dose of 10 mg twice daily for 7 days followed by 5 mg twice daily, and rivaroxaban was given at a dose of 15 mg twice daily for 21 days followed by 20 mg daily. The primary outcome was clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, as defined according to the International Society on Thrombosis and Haemostasis, during the 3-month trial period. Secondary outcomes included death from any cause. RESULTS:A total of 2760 patients underwent randomization: 1370 to the apixaban group and 1390 to the rivaroxaban group. A primary-outcome event occurred in 44 of 1345 patients (3.3%) in the apixaban group and 96 of 1355 patients (7.1%) in the rivaroxaban group (relative risk, 0.46; 95% confidence interval [CI], 0.33 to 0.65; P<0.001). Death from any cause occurred in 1 patient (0.1%) in the apixaban group and in 4 patients (0.3%) in the rivaroxaban group (relative risk, 0.25; 95% CI, 0.03 to 2.26). Serious adverse events unrelated to bleeding or venous thrombosis occurred in 36 patients (2.7%) in the apixaban group and in 30 patients (2.2%) in the rivaroxaban group. CONCLUSIONS:Among patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. (Funded by the Canadian Institutes of Health Research and others; COBRRA ClinicalTrials.gov number, NCT03266783.).

    2026The New England journal of medicine(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2From Anatomy to Ablation: Intracardiac Echocardiography-Guided Cavotricuspid Isthmus Morphology and Procedural Outcomes in Typical Atrial Flutter
    M Gabarin, M A Abonab, J G Acosta, A Alfraih, G Amit, J Bonacina, M Alrasheed, J Roberts, N Tan, S D Menon, J Wong, H Vivekanantham,

    Abstract Background Cavotricuspid isthmus (CTI) ablation is the standard treatment for typical atrial flutter (AFL), yet marked anatomical variability can influence procedural workload and outcomes. Intracardiac echocardiography (ICE) allows direct visualisation of isthmus morphology and may guide ablation strategy. Purpose To assess whether an ICE-derived CTI morphology score predicts ablation workload and clinical outcomes during fluoroless CTI ablation for typical AFL. Methods In a retrospective cohort of 200 consecutive patients undergoing CTI ablation guided by three-dimensional electroanatomical mapping and ICE, CTI anatomy was graded with a 0–6 morphology score combining five features: CTI length > 35 mm (1), pouch (1), ridge (1), thick or prominent Eustachian valve (2), and concave shape (1). Primary endpoints were radiofrequency (RF) ablation time and number of applications. Secondary endpoints were acute bidirectional CTI block and late AFL recurrence (> 3 months). Results Grades were mild 0–1 (58.5%), moderate 2–3 (35.5%), and severe 4–6 (6.0%). Acute block was achieved in 99.5%. Each 1-point higher CTI score predicted greater workload: approximately +50 s RF time and +4 additional applications per point (both p < 0.001). The score was not associated with acute success but showed a trend toward higher late AFL recurrence (7.0% overall). Complications were rare (1% groin haematoma). Conclusion(s) An ICE-derived CTI morphology score provides a reproducible intra-procedural measure of anatomical complexity, predicting ablation workload without compromising safety or acute success. Although its discrimination for late recurrence is modest, it offers practical value for procedural planning and operator guidance in fluoroless AFL ablation.C.I

    2026Europace(2026)
    引用
    AI阅读
    加入学术空间
    3TCT-498 Sustained Adoption and Impact of SMART AMI-ACS App on Case Selection and Door-in-Door-out Time in a High-Risk Acute Coronary Syndrome Network
    Mehdi Madanchi,Mathew Mercuri,Katelyn Cullen,Shamir Mehta,Tej Sheth,Sanjit Jolly,Natalia Pinilla,Michael Tsang,Matthew Sibbald,Nicholas Valettas,James Velianou,Alim Pardhan,
    2026JACC(2026)
    引用
    AI阅读
    加入学术空间
    4TCT-1336 Implementation of a Novel Structured Patient Safety Rounds for the Cardiac Catheterization Lab Using an Electronic Medical Record Trigger-Based Case Detection System
    Brian Bursic, Omar Ibrahim,Marc-Andre d'Entremont, Brian McGrath,Matthew Sibbald,Madhu Natarajan
    2026JACC(2026)
    引用
    AI阅读
    加入学术空间
    5TCT-157 Lactate Levels Predict Infarct Size and Mortality in STEMI Without Shock: an Analysis of the STEMI Door to Unload (DTU) Trial
    Edan Zitelny,Frans Beerkens, Gaurav Rana,Norman Mangner,James Udelson,Nima Aghili,Sanjit Jolly, Pablo Rengifo-Moreno,Florim Cuculi, David Manly,Amin Polzin, Hao Jiang,
    2026JACC(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 490 篇论文

    合作机构(100)

    麦克马斯特大学合作论文 174
    多伦多大学合作论文 42
    McGill University合作论文 22
    卡尔加里大学合作论文 22
    不列颠哥伦比亚大学合作论文 21
    汉密尔顿卫生科学合作论文 19
    劳森健康研究学院合作论文 19
    伦敦安大略西部大学合作论文 18
    Queen''s University合作论文 16
    渥太华大学(美国)合作论文 16

    机构统计